Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study

NCT01996267 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT01996267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01996267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 31, 2013
Completion date
December 31, 2030
Enrollment
437 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 positive